KLK3 and prostate cancer: Our study demonstrates the high impact of 68Ga-PSMA-11-PET/CT for patients with prostate cancer regarding therapy planning and emphasizes how important the examination is for all patient groups in their individual situation, suggesting that key clinical indicators, including the risk classification, Gleason score, and PSA level, have an impact on treatment decisions.